NCT04709328View on ClinicalTrials.gov

To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

690

Participants

Timeline

Start Date

March 28, 2021

Primary Completion Date

January 1, 2022

Study Completion Date

March 1, 2022

Conditions

COVID-19SARS-CoV-2

Interventions

DRUG

SCTA01

Diluted by 0.9% normal saline，IV

OTHER

Placebo

IV

All Listed Sponsors

lead

Sinocelltech Ltd.

INDUSTRY